

Wednesday July 4, 2018

07:30 Registration

08:30 Opening and Inaugural Lecture

09:00 PL01 - Disrupting Cancer Care & Outcomes by Putting Patients in the Driving Seat

Dr Anne BRUINVELS
(PX HEALTHCARE, London, United Kingdom)

Session 1 - New Breakthrough in GPCR Structure, Function and Drug Discovery

09:45 PL02 - Novel Modes of Chemical Regulation of GPCRs

Prof. Graeme MILLIGAN
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

10:30 Coffee break and Exhibition

11:00 PL03 - Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism

Dr Patrick SCHNIDER
(ROCHE PHARMACEUTICAL, Basel, Switzerland)

11:45 PL04 - Ghrelin Receptor Ligands: from the Bench to the Drug!

Dr Jean-Alain FEHRENTZ
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)

12:30 Lunch

13:00 Poster session and Exhibition

14:30 PL05 - Structure-Based Drug Discovery for G Protein-Coupled Purine Receptors

Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)

15:15 PL06 - Structure-guided Development of Selective GPCR Ligands

Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

16:00 Coffee break and Exhibition

Session 2 - Novel Synthetic Methods For Therapeutic Innovation

16:30 PL07 - Late Stage Fluorination for Medicine

Prof. Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

17:15 PL08 - Single Electron Processes Enabling Organic Synthesis

Programme

Prof. Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

18:00 **Welcome and networking reception**

Thursday July 5, 2018

08:30 PL09 - Paul Ehrlich Award Lecture - Chemical Biology on the Genome

Prof. Shankar BALASUBRAMANIAN
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Session Session 3 - Biologically Active Chemical Space

09:30 PL10 - Ancient and Modern Scaffolds for Biologically Active Chemical Space

Prof. Arasu GANESAN
(UNIVERSITY OF EAST ANGLIA, Norwich, United Kingdom)

Session Session 4 - Chemokine Targeted Drug Discovery

PL11 - Decoy Chemokine Ligands Targeting CXCL12, CCL17 and CCL22: Discovery and Anti-inflammatory Activity

Dr Jean-Luc GALZI
(CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France)

10:15 Coffee break and Exhibition

Session Session 5 - Advances in GPCR drug discovery

11:00 KL01 - Discovery of The Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure

Dr Carsten SCHMECK
(BAYER, Wuppertal, Germany)

11:30 KL02 - Discovery of New Brain Penetrating Neuropeptide S Receptor (Npsr) Antagonists

Dr Julien POTHIER
(IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland)

Session Session 6 - Advances in Biological Imaging

KL03 - Dye-loaded Lipid Nanoparticles: Contrast Agents for Image-guided Surgery and Tools for Drug Delivery

Dr Isabelle TEXIER
(LETI-HEALTH, Grenoble, France)

KL04 - Inducible Chemical-genetic Fluorescent Markers for Bioimaging

Dr Arnaud GAUTIER
(ECOLE NORMALE SUPÉRIEURE, Paris, France)

12:00 Lunch

12:30 Poster session and Exhibition

Session Session 7 - Challenging Targets and Approaches

14:00 PL12 - Discovery of Foliglurax, an mGluR4 PAM for the Treatment of Parkinson's Disease.

Dr Stephan SCHANN
(DOMAIN THERAPEUTICS SA, Illkirch, France)

14:45 PL13 - Potential Therapeutic Targets in the Brain Renin-Angiotensin and Apelinergic Systems for Treatment of Cardiovascular Diseases

Dr Catherine LLORENS-CORTES
(INSERM-COLLÈGE DE FRANCE, Paris, France)

15:30 KL05 - Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering

Programme

Dr Julie CHARTON
(UNIVERSITY OF LILLE, INSTITUT PASTEUR DE LILLE, Lille, France)

Session Session 8 - Understanding Binding Characteristics

PL14 - Pharmacophore-based Analysis of Molecular Dynamics Trajectories: Towards Understanding KD of Protein Ligands

Prof. Thierry LANGER
(UNIVERSITY OF VIENNA, Vienna, Austria)

PL15 - Identifying Inter-Helical Interactions Involved in GPCR Structure-Function and the Forces that Determine Receptor-Ligand Residence Time

Dr Alexander HEIFETZ
(EVOTEC, Abingdon, United Kingdom)

KL06 - Drug-target Residence Time – a Misleading Concept

Dr Rutger FOLMER
(MERCACHEM, Nijmegen, The Netherlands)

16:00 Coffee break and Exhibition

Session Session 9 - Tackling Challenges in Drug Delivery

16:30 PL16 - Cellular Delivery and Oral Uptake of Cyclic Peptides

Dr Thomas VORHERR
(NOVARTIS, Basel, Switzerland)

17:15 PL17 - Nanoparticle-based Strategies in Oncology

Prof. Jean-Pierre BENOIT
(UNIVERSITY OF ANGERS, Angers, France)

Session Session 10 - Chemistry Driven Biological Exploration

PL18 - Chemistry as the Helping Tool to Develop New Therapeutic Strategies

Prof. Maria Luz LOPEZ-RODRIGUEZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

PL19 - Chemical Tools to Probe Reversible Lysine Acetylation

Prof. Manfred JUNG
(ALBERT LUDWIGS UNIVERSITY OF FREIBURG, Freiburg, Germany)

Friday July 6, 2018

Session 11 - New modalities in Drug Discovery

- 08:30** **PL20 - PROTAC-mediated Protein Degradation: A New Therapeutic Modality**
Prof. Craig CREWS
(UNIVERSITY OF YALE, New Haven, United States)
- 09:15** **PL21 - The Confobody technology, a New Platform to Enable Fragment Screening on GPCRs**
Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)
- 10:00** **Coffee break and Exhibition**

Session 12 - Chemistry in Living Systems

- 10:30** **PL22 - Two Adventures in Chemical Biology - in vivo chemistry and real-time optical medical imaging.**
Prof. Mark BRADLEY
(UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom)
- 11:15** **PL23 - Therapeutic In Vivo Synthetic Chemistry**
Prof. Nori TANAKA
(RIKEN, Saitama, Japan)
- 12:00** **PL24 - Pierre Fabre Award lecture**
- 13:00** **Concluding remarks**